Conference Coverage
Latest News
Nov 06, 2025 | News
Preliminary Phase 2 Data Support Therapeutic Development of Synaptic Regenerative Drug SPG302 in ALS
Dental Caries and Periodontal Disease Increase Ischemic Stroke Risk, Study Shows
Nov 05, 2025
FDA Feedback Provides Clarity for Phase 3 Trial of Neflamapimod in Dementia With Lewy Bodies
Nov 05, 2025
FDA Issues Complete Response Letter for Spinocerebellar Ataxia Agent Troriluzole
Nov 05, 2025
Acute Stroke Therapy LT3001 Eyes Phase 3 Studies Following Positive Phase 2b Data
Nov 05, 2025
Advertisement
Shorts
1:15
Evolving Landscape of Myasthenia Gravis Treatment
3 days ago
by
Leila Darki, MD(+1 more)
1:05
Aerobic Exercise and Promoting Remyelination in MS
17 days ago
by
Lindsey Wooliscroft, MD, MS(+1 more)
1:12
MDS 2025: Learning From Progress in Other Disease States
a month ago
by
Lorraine Kalia, MD, PhD(+1 more)
1:16
MDS 2025: Biologically Defining Parkinson Disease
a month ago
by
Tanya Simuni, MD, FAAN(+1 more)
1:32
MDS 2025: Environmental Exposures and PD
a month ago
by
Web Ross, MD(+1 more)
0:53
MDS 2025: Novel Therapeutics and Biomarkers for PD
a month ago
by
Veronica Santini, MD, MA(+1 more)
0:38
MDS 2025: PD and the Gut Microbiome
a month ago
by
Samia Ben Sassi, MD(+1 more)
1:49
MDS 2025: Parkinson Disease and Brain Organization
a month ago
by
A. Jon Stoessl, CM, MD(+1 more)
0:53
MDS 2025: Exercise and Diet's Impact on Parkinson Disease
a month ago
by
Jonas Hannestad, MD, PhD(+1 more)
1:21
Migraine Care Needs of the LGBTQIA+ Patient Population
a month ago
by
Anna Pace, MD(+1 more)
Coverage of MDS Congress 2025
Get direct access to interviews with experts, as well as the latest data and clinical news updates, straight from the conference floor in Honolulu.
Coverage of AANEM 2025
Get direct access to interviews with experts, straight from the conference floor in San Francisco, as well as the latest data and clinical news updates.
Mind Moments Podcast
Mind Moments® is a biweekly podcast from NeurologyLive that brings you exclusive interviews with expert neurologists and clinicians.
DAMM Good Sleep
Check out DAMM Good Sleep × NeurologyLive for neurology-focused sleep content to allow any neurology stakeholder to use sleep as the diagnostic, prognostic, and therapeutic neurology tool it should be.
NeuroVoices
NeuroVoices is NeurologyLive's series of in-depth, exclusive Q&A conversations with a variety of experts in the care and management of patients with neurologic diseases about topics in clinical care and therapeutic development.
Videos
Podcasts
Continuing Medical Education
Advertisement
All News
Advertisement
The associate professor of physical medicine and rehabilitation at Virginia Commonwealth University discussed his passion for educating others about electrodiagnosis and ultrasound in neuromuscular disorders.
A physician assistant who specializes in neurology previewed her upcoming presentation on evaluating patients with headache at the 2025 Baptist Miami Neuroscience Symposium.
A phase 3 study evaluates remibrutinib's safety and efficacy for generalized myasthenia gravis, promising new treatment options for patients.
A phase 1/2 trial explores YTB323, a CAR T cell therapy, for treating generalized myasthenia gravis, aiming to enhance patient outcomes and safety.
A phase 3 study will evaluate iptacopan's efficacy in treating generalized myasthenia gravis, focusing on daily living activities and safety outcomes.
UCB's Kygevvi becomes the first FDA-approved treatment for thymidine kinase 2 deficiency, offering hope to patients with this rare neuromuscular disorder.
Gregory Hawryluk, MD, PhD, a neurosurgeon at Cleveland Clinic, spoke on the development and clinical impact of new global guidelines for penetrating traumatic brain injury.
Here's some of what is coming soon to NeurologyLive® this week.
The chief medical officer at Mandos Health discussed new CNS 2025 data on adrabetadex in infantile-onset Niemann-Pick type C and the growing evidence of its potential disease-modifying impact.
Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on the 2025 AANEM Annual Meeting!
Advertisement
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending October 31, 2025.
Salvia BioElectronics’ PRIMUS system, currently being assessed in a clinical trial, delivers subcutaneous occipital and supraorbital nerve stimulation for patients with resistant migraine.
Avi Singh Gandh, MD, neurology resident at Emory University School of Medicine, reflected on how modern neurology can help interpret the Salem witch trials.
Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Rebecca Edelmayer, PhD. [LISTEN TIME: 14 minutes]
A groundbreaking trial compares nipocalimab and efgartigimod for treating generalized myasthenia gravis, promising new insights for patient care.
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Dental Caries and Periodontal Disease Increase Ischemic Stroke Risk, Study Shows
2
FDA Issues Complete Response Letter for Spinocerebellar Ataxia Agent Troriluzole
3
Preliminary Phase 2 Data Support Therapeutic Development of Synaptic Regenerative Drug SPG302 in ALS
4
FDA Feedback Provides Clarity for Phase 3 Trial of Neflamapimod in Dementia With Lewy Bodies
5
